The thesis

Madrigal Pharmaceuticals is a biopharmaceutical company with a high revenue growth rate of 71.2% YoY. Its conviction score is 39/100, indicating a watchlist status. The analyst consensus rating is BUY, despite a negative P/E ratio of -41.9x and a net margin of -2532.0%. This discrepancy makes the company's setup interesting,

Why now

The current macro context, with the US-China squeeze and Middle East war, may impact the company's valuation and growth prospects. The company's high revenue growth rate and negative margins make it a compelling story to watch, especially with a conviction score below 50,

What to watch

The company's future revenue growth rates and margin expansion will be key indicators to watch over the next 1-3 quarters. Specifically, a reduction in net losses and an improvement in gross margin percentage will be crucial in confirming or denying the thesis,

Key risks

The company's high valuation risk, with a DCF intrinsic value of $2719, may not be justified by its financial performance. Execution risk is also a concern, given the company's negative net margin and high research and development costs. Additionally, competitive risk from established pharmaceutical companies may impact MDGL's market share,